摘要
目的:研究导管原位癌中雄激素受体(androgen receptor,AR)的表达情况,探讨AR表达与组织分级及与雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)表达的关系。方法:用免疫组织化学方法研究51例不同级别导管原位癌(breast ductal carcinoma in situ,DCIS)中AR的表达及与ER、PR表达状态的相关性。结果:AR阳性表达于18例DCIS中,33例DCIS中没有表达。13例低级别导管内癌中有3例AR阳性表达,15例中级导管内癌中有7例AR阳性表达,23例高级导管内癌中有8例AR阳性表达(P=0.4270)。导管内癌的分化程度与ER(P=0.0036)及PR(P=0.0398)的表达密切相关。在导管内癌的不同组织学亚型间AR的表达差异有统计学意义(P=0.0156),但ER(P=0.0695)与PR(P=0.4672)的表达无差异。绝经前与绝经后患者导管内癌的AR表达无差异(P=0.6510),但ER(P=0.0074)与PR(P=0.0259)的表达有差异。结论:有一部分乳腺导管内癌表达AR,导管内癌的AR表达与组织分化程度无关,与DCIS中ER、PR表达也没有相关性。
Objective： To study the expression of androgen receptors（ AR） in ductal carcinoma in situ（ DCIS） of breast and relation with histological grade. Methods： AR expression was examined in 51 cases of DCIS of the breast and correlated to the degree of differentiation and ER / PR expressing status by using immunohistochemical method.Results： AR positivity was noted in 18 of the cases,the other 33 cases were negative. Three of the 13 low grade DCIS cases,7 of the 15 intermediately differentiated cases,and 8 of the 23 high grade cases were positive（ P = 0. 4270）.However,there was a strong association between the expression of ER（ P = 0. 0036） and PR（ P = 0. 0398） and the degree of differentiation of DCIS. Otherwise,different histological subtypes of DCIS showed significant difference to the expression of AR（ P = 0. 0156）,but no difference was found in the expression of ER（ P = 0. 0695） and PR（ P =0. 4672）. AR expression was no difference between the patients of pre- and postmenopausal（ P = 0. 6510）,but it was showed difference of ER（ P = 0. 0074） and PR（ P = 0. 0259） expression. Conclusion： A large mumber of cases of DCIS of the breast express AR,the expression of AR in DCIS does not have to be association with the degree of differentiation,and no relationship was found with the expressing status of ER and PR in DCIS.
出处
《现代肿瘤医学》
CAS
2014年第12期2853-2856,共4页
Journal of Modern Oncology
基金
上海市浦东新区科技发展基金创新资金资助项目(编号:PKJ2012-Y67)
关键词
乳腺导管原位癌
免疫组化
雄激素受体
雌激素受体
孕激素受体
breast ductal carcinoma in situ （ DCIS ）
immunohistochemistry
androgen receptor （AR）
estrogen receptor （ER）
progesterone receptor （ PR ）
